



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/075,909	02/13/2002	Nicole Chantel Barvian	A0000517-01-CFP	9232
28880	7590 12/13/2004		EXAMINER	
WARNER-LAMBERT COMPANY 2800 PLYMOUTH RD			TRUONG, TAMTHOM NGO	
	R, MI 48105		ART UNIT	PAPER NUMBER
	•		1624	

DATE MAILED: 12/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/075,909	BARVIAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Tamthom N. Truong	1624			
, The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed /s will be considered timely. If the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
 Responsive to communication(s) filed on <u>9-23-</u> This action is FINAL. Since this application is in condition for allowar closed in accordance with the practice under <i>E</i> 	action is non-final.				
Disposition of Claims					
4) Claim(s) 9,11,15 and 22-24 is/are pending in the 4a) Of the above claim(s) 15 is/are withdrawn from 5) Claim(s) 9 and 22-24 is/are allowed. 6) Claim(s) 11 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or are subject to restriction and/or are subject to by the Examined 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examined 11.	relection requirement. r. epted or b) objected to by the drawing(s) be held in abeyance. Section is required if the drawing(s) is objected to by the drawing(s).	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)					
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>9-23-04</u>. 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Application/Control Number: 10/075,909 Page 2

Art Unit: 1624

DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 09-23-04 has been entered.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 2. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:
 - 1. Determining the scope and contents of the prior art.
 - 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent art.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Application/Control Number: 10/075,909

Page 3

Art Unit: 1624

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over **Baader et. al.** (US 5,130,317). On column 1, Baader et. al. disclose a genus of formula I which renders obvious a few compounds recited in the instant claim 7. Then, on column 7, Baader et. al. disclose the compound of *Pyrimidine-4,6-dicarboxylic acid dibenzylamide* (see Example 2), which the common core of some compounds in the instant claim 11 (for example, 13th, 15th and 16th compounds). The disclosed compound differs from the claimed compounds by not having substituent(s). However, the genus of formula I on column 2 allows for substitution on the *benzyl* ring (or R¹). Since the list of substituents on R¹ was limited to only five groups, the equivalent teaching would provide the motivation for one of the ordinary skilled in the art to select compounds having a substituted benzyl ring such as those claimed herein. Therefore, at the time of the invention, it would have been obvious for one skilled in the art to select the above compounds of claim 11 because one would have expected them to inhibit proline hydroxylase and lysine hydroxylase as taught by Baader et. al.

Status of Claims 9, 15, and 22-24

3. Claims 9, and 22-24 appear to be free of prior art. Claim 15 is currently withdrawn.

Information Disclosure Statement

4. The information disclosure statement (IDS) submitted on 9-23-04. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 571-272-0676. The examiner can normally be reached on M-F (10:00-6:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Tamthom N. Truong

Examiner

Art Unit 1624

12-08-04

JAMES O. WILSON

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600